Assistant Professor of Medicine, Rush Medical College
Gastroenterology
Dr. Scott J. Cotler, MD
|
|
Give Review
Dr. Scott J. Cotler is an expert in the field of Gastroenterology. He went to medical school at University of Chicago Pritzker School of Medicine. University of Chicago Pritzker School of Medicine is ranked 10/19 in Research/PrimaryCare. He received 3 awards: "West Suburban Living Magazine", "CMS Meaningful Use Stage 1 Certification" and "Super Doctor". Scott J. Cotler is also published. He has 100 publications published. The lastest publication: "Donor-recipient sharing of HLA class II alleles predicts earlier recurrence and accelerated progression of hepatitis C following liver transplantation.' He accepts Medicare.
Publications
- The distribution of Hepatitis B virus exposure and infection in a population-based sample of US Hispanic adults.
- Oral prenylation inhibition with lonafarnib in chronic Hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.
- Prevalence of suspected nonalcoholic Fatty liver Disease in hispanic/latino individuals differs by heritage.
- Understanding early serum Hepatitis D virus and Hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.
- Sustained virological Response with intravenous silibinin: individualized IFN-free therapy via real-time modeling of HCV kinetics.
- FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.
- Presurgical transarterial chemoembolization does not increase Biliary stricture incidence in orthotopic liver transplant patients.
- Severity of liver Disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy.
- Association of genetic variants with rapid fibrosis: progression after liver transplantation for Hepatitis C.
- Prevalence and Correlates of Suspected Nonalcoholic Fatty Liver Disease in Chinese American Children.
- Biomechanics and functionality of hepatocytes in liver Cirrhosis.
- Individualized treatment for patients with low HCV load (genotype 1): A viral kinetic approach.
- Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the Hepatitis C virus half-life.
- Prognostic capability of different liver disease scoring Systems for prediction of early mortality after transjugular intrahepatic portoSystemic shunt creation.
- Quantitative morphometric analysis of hepatocellular carcinoma: development of a programmed algorithm and preliminary application.
- Barriers to Treatment of Hepatitis B in an Urban Chinatown Community.
- TIPS for Treatment of Variceal Hemorrhage: Clinical Outcomes in 128 Patients at a Single Institution over a 12-Year Period.
- Characterization of antigenic variants of Hepatitis C virus in immune evasion.
- Chronic Hepatitis C virus infection and increases in viral load in a prospective cohort of young, HIV-uninfected injection drug users.
- Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV Response as a function of IL28B polymorphism in HIV/HCV-coinfected patients.
- Potential treatment options and future research to increase Hepatitis C virus treatment response rate.
- Ethnicity and body mass index are associated with Hepatitis C presentation and progression.
- ReBleeding rates following TIPS for variceal hemorrhage in the Viatorr era: TIPS alone versus TIPS with variceal embolization.
- Hepatitis B seroprevalence and Disease characteristics in an urban Chinatown community.
- Hepatitis B virus clearance rate estimates.
- A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver Disease.
- Liver Injury with Features Mimicking Autoimmune Hepatitis following the Use of Black Cohosh.
- The histologic spectrum of liver Disease in African-American, non-Hispanic white, and Hispanic obesity surgery patients.
- Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of Cirrhosis?
- Care of the liver transplant patient.
- Ethnicity and nonalcoholic fatty liver Disease in an obesity clinic: the impact of triglycerides.
- How physicians describe outcomes to HCV therapy: prevalence and meaning of "cure" during provider-patient in-office discussions of HCV.
- Immunohistochemical expression of components of the Akt-mTORC1 pathway is associated with hepatocellular carcinoma in patients with chronic liver Disease.
- A pilot study of vasculogenic mimicry immunohistochemical expression in hepatocellular carcinoma.
- Liver enzymes and histology in obese patients with obstructive sleep apnea.
- Diabetes and hepatic oxidative damage are associated with Hepatitis C progression after liver transplantation.
- Screening for hepatocellular carcinoma in clinical practice: miles to go before we sleep.
- Laboratory diagnosis and nonoperative management of Biliary complications in living donor liver transplant patients.
- Measurement of liver fat content using selective saturation at 3.0 T.
- Alpha-methylacyl-CoA racemase (AMACR/P504S) can distinguish hepatocellular carcinoma and dysplastic hepatocytes from Benign nondysplastic hepatocytes.
- Liver transplantation for hepatocellular carcinoma: a survey of practices.
- Productive replication of Hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism.
- Provider-patient in-office discussions of response to Hepatitis C antiviral therapy and impact on patient comprehension.
- p53, Ki-67, and serum alpha feto-protein as predictors of hepatocellular carcinoma recurrence in liver transplant patients.
- Management of Hepatitis B in liver transplant patients.
- Hepatic decompensation after Gastric bypass surgery for severe obesity.
- Prevalence and significance of autoantibodies in patients with non-alcoholic steatoHepatitis.
- Hepatitis C treatment eligibility in an urban population with and without HIV coinfection.
- Antiviral Therapy for Hepatitis C.
- Neutralizing antibodies in Hepatitis C virus infection: a review of immunological and clinical characteristics.
- Adult living donor liver transplantation: perspectives from 100 liver transplant surgeons.
- A pilot study of the combination of cyclosporin A and interferon alfacon-1 for the treatment of Hepatitis C in previous nonresponder patients.
- Hepatitis C, iron status, and Disease severity: relationship with HFE mutations.
- Characteristics of Hepatitis C in renal transplant candidates.
- Induction of IL-1Ra in resistant and responsive Hepatitis C patients following treatment with IFN-con1.
- Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes.
- Black cohosh (Actaea racemosa) for the mitigation of menopausal symptoms: recent developments in clinical safety and efficacy.
- Ethnic and geographical differences in HLA associations with the outcome of Hepatitis C virus infection.
- Modelling Hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay.
- Is percutaneous liver biopsy safe in patients with hepatitis C and end-stage renal Disease?
- Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver Disease.
- Viral kinetics in the treatment of chronic Hepatitis C.
- Prevalence of hepatic iron overload and association with hepatocellular Cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry.
- Survival after liver transplantation in patients with hepatic iron overload: the national Hemochromatosis transplant registry.
- Simple clinical variables predict liver histology in Hepatitis C: prospective validation of a clinical prediction model.
- Serological markers of autoimmunity in patients infected with Hepatitis C virus: impact of HIV co-infection.
- A multicentre study of the usefulness of liver biopsy in Hepatitis C.
- A comparison of Hepatitis C treatment and outcomes at academic, private and Veterans'' Affairs treatment centres.
- First phase Hepatitis c viral kinetics in previous nonresponders patients.
- Hepatitis C virus infection and lung transplantation: a survey of practices.
- Relationship between iron concentration and Hepatitis C virus RNA level in liver tissue.
- In situ distribution of hepatitis C virus replicative-intermediate RNA in hepatic tissue and its correlation with liver Disease.
- Hyperbilirubinemia and cholestatic liver injury in Hepatitis C-infected liver transplant recipients.
- Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for Hepatitis C.
- Efficacy of endoscopic management of anastomotic Biliary strictures after hepatic transplantation.
- Daily interferon therapy for Hepatitis C virus infection in liver transplant recipients.
- Adult living donor liver transplantation: Preferences about donation outside the medical community.
- Resolution of Cirrhosis in autoimmune hepatitis with corticosteroid therapy.
- Physicians'' preference values for Hepatitis C health states and antiviral therapy: a survey.
- Patients' values for health states associated with Hepatitis C and physicians' estimates of those values.
- Treatment of Hepatitis C virus and HIV co-infections.
- An analysis of acute changes in interleukin-6 levels after treatment of Hepatitis C with consensus interferon.
- Pancreas-graft immunogenicity and pretreatment with anti-class II monoclonal antibodies.
- Hepatitis G virus co-infection does not alter the course of recurrent Hepatitis C virus infection in liver transplantation recipients.
- End-stage liver Disease without hemochromatosis associated with elevated hepatic iron index.
- Donor-recipient sharing of HLA class II alleles predicts earlier recurrence and accelerated progression of Hepatitis C following liver transplantation.
- The prevalence and clinical correlates of elevated ALT levels in an urban Chinatown community.
- Very early prediction of Response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients.
- Hepatocyte proliferation and Hepatitis C virus kinetics during treatment.
- Characterizing Hepatitis B stigma in Chinese immigrants.
- Management of the kidney transplant patient with chronic Hepatitis C infection.
- Challenges for Hepatitis C patients coinfected with HIV.
- Thymoglobulin induction protects liver allografts from ischemia/reperfusion injury.
- Ethnic differences in the presentation of chronic Hepatitis C.
- Hepatic ischemia/reperfusion injury can be modulated with thymoglobulin induction therapy.
- The protein kinase-interacting domain in the Hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon.
- Advances in liver transplantation: overview and status.
- 35-year-old patient with chronic myelogenous leukemia developing Systemic lupus erythematosus after alpha-interferon therapy.
- The Metabolism of acitretin and isoacitretin in the in situ isolated perfused rat liver.
Schools
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
University Chicago Hosps
Rush Presby St Lukes Hospital
University Wa
Procedures Preformed
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
- ERCP (Endoscopic Retrograde Cholangiopancreatography)
- Liver Biopsy
Conditions Treated
- Abdominal Pain
- Anemia
- Benign Neoplasm of the Digestive System
- Biliary Atresia
- View All
Doctors Specialties
- Gastroenterology
- Transplant Hepatology
Accepted Insurances
Awards
- West Suburban Living Magazine
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
University of Washington -
Rush University Medical Center -
University of Chicago -
University of Chicago Pritzker School of Medicine
Hospital
-
University of Illinois Hospital & Health Sciences System -
Jesse Brown Veterans Affairs Medical Center -
Mercy Hospital and Medical Center
Drug Facts
| NPI NUMBER | 1225142730 | |
| NPPES Provider LastName | COTLER | |
| NPPES Provider FirstName | SCOTT | |
| NPPES Provider ZIPCode | 601533328 | |
| NPPES Provider State | IL | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 1555.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 92.0 | |
| Percent Opioid Claims | 5.92 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1225142730 |
| Last Name Of The Provider | COTLER |
| First Name Of The Provider | SCOTT |
| View All |
Similar Doctors
|
|
Dr. Anjana A. Pillai, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Claus T. Fimmel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arvin K. Bhatia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer A. Dorfmeister, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Natasha M. Von Roenn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mukund Venu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edwin J. Zarling, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marla Z. Wolfert, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas Schnell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Klamut, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Omar Khan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rebecca W. Tsang, MD
This Doctor is OpenDoctor Recommended.
|